Technical Analysis for TERN - Terns Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 4.70 -2.08% -0.10
TERN closed down 2.08 percent on Thursday, September 28, 2023, on 60 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Gapped Up Strength 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -2.08%
BB Squeeze + Lower Band Touch Range Contraction -2.08%
Below Lower BB Weakness -2.08%
Lower Bollinger Band Touch Weakness -2.08%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 9 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Gap Up Closed about 13 hours ago
Gap Up Partially Closed about 13 hours ago
Down 3% about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Terns Pharmaceuticals, Inc. Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Bile Acid Chronic Liver Diseases Glucagon Anti Diabetic Drugs

Is TERN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.0435
52 Week Low 4.38
Average Volume 602,565
200-Day Moving Average 9.11
50-Day Moving Average 5.93
20-Day Moving Average 5.19
10-Day Moving Average 5.10
Average True Range 0.33
RSI (14) 30.56
ADX 40.25
+DI 13.11
-DI 29.43
Chandelier Exit (Long, 3 ATRs) 4.65
Chandelier Exit (Short, 3 ATRs) 5.60
Upper Bollinger Bands 5.57
Lower Bollinger Band 4.81
Percent B (%b) -0.15
BandWidth 14.68
MACD Line -0.30
MACD Signal Line -0.32
MACD Histogram 0.0188
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.20
Resistance 3 (R3) 5.22 5.07 5.11
Resistance 2 (R2) 5.07 4.95 5.06 5.08
Resistance 1 (R1) 4.89 4.87 4.82 4.87 5.06
Pivot Point 4.74 4.74 4.71 4.73 4.74
Support 1 (S1) 4.56 4.62 4.49 4.54 4.34
Support 2 (S2) 4.41 4.54 4.40 4.32
Support 3 (S3) 4.23 4.41 4.29
Support 4 (S4) 4.21